Is age an independent risk factor for chemically induced acute myelogenous leukemia in children?

Journal of Toxicology and Environmental Health - Part B: Critical Reviews

Volumn 10, Issue 5, 2007, Pages 379-400

  Pyatt, David W ^a,b   Aylward, Lesa L ^a   Hays, Sean M ^a  

^a LLP   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; NITROSOUREA; PREDNISOLONE; PROCARBAZINE; TENIPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; AGE DISTRIBUTION; ARTICLE; BONE CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICALLY INDUCED DISORDER; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; HODGKIN DISEASE; HUMAN; LEUKEMOGENESIS; METASTASIS; MYELODYSPLASTIC SYNDROME; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; THYROID CANCER; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; DNA TOPOISOMERASES, TYPE II; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 34547813728     PISSN: 10937404     EISSN: 15216950     Source Type: Journal    
DOI: 10.1080/15287390600975061     Document Type: Article

References (90)

1. Abrahamsen, J., Andersen, A., Hannisdal, E., Nome, O., Abrahamsen, A., Kvaloy, S., and Host, H. 1993. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time and age. J. Clin. Oncol. 11:255-261.
2. Aksoy, M., Dincol, K., Erdem, S., and Dincol, G. 1972. Acute leukemia due to chronic exposure to benzene. Am. J. Med. 52:160-166.
3. Anderson, M., Larson, R., Mauritzson, N., Schnittger, S., Jhanwar, S., and Pedersen-Bjergaard, J. 2002. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: Report from an international workshop. Genes, Chromosomes Cancer. 33:395-400.
4. Andrieu, J., Ifrah, N., Payen, C., Fermanian, J., Coscas, Y., and Flandrin, G. 1990. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J. Clin. Oncol. 8:1148-1154.
5. Beaty, O., Hudson, M., Greenwald, C., Luo, X., Fang, L. and Pratt, C. 1995. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J. Clin. Oncol. 13:603-609.
6. Beaumont, M., Sanz, M., Carli, P.M., Maloisel, X., Thomas, L. and Fenaux, P. 2003. Therapy-related acute promyelocytic leukemia. J. Clin. Oncol. 21:2123-2137.
7. Bhatia, S., Yasui, Y., Robinson, L., Birch, J., and Bogue, M. 2003. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the Late Effects Study Group. J. Clin. Oncol. 21:4386-4394.
8. Boice, J. D., Blettner, M., Kleinerman, R. A., Stovall, M., Moloney, W. C., Engholm, G., Austin, D. F., Bosch, A., Cookfair, D. L., and Krementz, E. T. 1987. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J. Nat. Cancer Inst. 79:1295-1311.
9. Boivin, J., Hutchison, G., Zauber, A., Bernstein, L., Davis, F., Michel, R., Zanke, B., Tan, T., Fuller, L., Mauch, P. and Ultmann, J. 1995. Incidence of second cancers in patients treated for Hodgkin's disease. J. Nat. Cancer Inst. 87:732-741.
10. Bond, G. G., McLaren, E. A., Baldwin, C. L. and Cook, R. R. 1986. An update of mortality among chemical workers exposed to benzene. Br. J. Ind. Med. 43:685-691.
11. Bowen, D. T. 2000. Oxidative stress and the myelodysplastic syndromes. Leukocyte Res. 24:139-140.
12. Coleman, N., Kaplan, H., Cox, R., Varghese, A., Butterfield, P., and Rosenburg, S. 1982. Leukemias, non-Hodgkin's lymphoma and solid tumors in patients treated for Hodgkin's disease. Cancer Surv. 1:733-744.
13. Coltman, C. A. and Dahlberg, S. 1990. Treatment-related leukemia. N. Engl. J. Med. 322:52-53.
14. De Renzo, A., Santoro, L. F. E., Notaro, R., Pane, F., Buonaiuto, M. R., Luciano, L., and Rotoli, B. 1999. Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase II. Am. J. Hematol. 60:300-304.
15. Dedrick, R. L., and Morrison, P. F. 1992. Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res. 52:2464-2467.
16. Deley, M., Leblanc, T., Shamsaldin, A., ARaguin, M., Lacour, B., Sommelet, D., Chompret, A., Cayuela, J., Bayle, C., Bernheim, A., Vathaire, F., Vassal, G. and Hill, C. 2003. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Societe Francaise d'Oncologie Pediatrique. J. Clin. Oncol. 21:1074-1081.
17. Dores, G., Metayer, C., Curtis, R., Lynch, C., Clarke, A., and Travis, L. 2002. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation of over 25 years. J. Clin. Oncol. 20:3484-3494.
18. Farahati, J., Demidchik, E., Biko, J., and Reiners, C. 2000. Inverse association between age at the time of radiation exposure and extent of disease in cases of radiation-induced childhood thyroid carcinoma in Belarus. Cancer 88:1470-1476.
19. Garwicz, S., Anderson, H., Olsen, J., Dollner, H., Hertz, H., Jonnundsson, G. and Tulinius, H. 2000. Second malignant neoplasms after cancer in childhood and adolescence: A population-based case-control study in the 5 Nordic countries. Int. J. Cancer. 88:672-678.
20. Glaubiger, D., von Hoff, D., Holcenberg, J., Kamen, B., Pratt, C., and Ungerleider, R. 1982. The relative tolerance of children and adults to anticancer drugs. Front. Radiat. Ther. Oncol. 16:42-49.
21. Glicksman, A., Pajak, T., Gottieb, A., Nissen, N., Stutzman, L., and Cooper, M. 1982. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: A cancer and leukemia Group B study. Cancer Treatment Rep. 66:1035-1044.
22. Hamilton, A. 1922. The growing menace of benzene (benzol) poisoning in American industry. J. Am. Med. Assoc. 78:627.
23. Haskell, C. M. 1990. Drugs used in cancer chemotherapy. In Cancer treatment, ed. C. M. Haskell, pp. 44-102. Philadelphia: W. B. Saunders.
24. Hawkings, M., Wilson, L., Stoival, M., Marsden, H., Potok, H., and Chessells, J. 1992. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukemia after childhood cancer. Br. Med. J. 304:951-957.
25. Henry-Amar, M. 1991. Second cancer after the treatment for Hodgkin's disease: A report from the International database on Hodgkin's disease. Ann. Oncol. 4:117-128.
26. Hoffmann, L., Moller, P., Pedersen-Bjergaard, J., Wagge, A., Pedersen, M., and Hirsch, F. R. 1995. Therapy-related acute promyelocytic leukemia with t(15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann. Oncol. 6:781-788.
27. Infante, P. F., Rinsky, R. A., Wagoner, J. K., and Young, R. J. 1977. Leukemia in benzene workers. Lancet. 2:76-78.
28. Ishimaru, T., Otake, M., and Ichimaru, M. 1979. Dose-response relationship of neutrons and gamma rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950-1971. Radiat. Res. 77:377-394.
29. Jandl, J. H. 1997. Blood, Textbook of hematology. Boston: Little, Brown.
30. Jenkin, D., Grennberg, M., and Fitzgerald, A. 1996. Second malignant tumors in childhood Hodgkin's disease. Med. Pediat. Oncol. 26:373-379.
31. Jenkinson, H., Hawkins, M., Stiller, C., Winter, D., Marsden, H., and Stevens, M. 2004. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br. J. Cancer 91:1905-1910.
32. Johansson, B., Mertens, F., Heim, S., Kristoffersson, U., and Mitelman, F. 1991. Cytogenetics of secondary myelodysplasia (s-MDS. and acute nonlymphocytic leukemia (s-ANLL). Eur. J. Haematol. 47:17-27.
33. Kacew, S., and Lemaire, I. 2000. Recent developments in benzene risk assessment. J. Toxicol. Environ. Health A 61:485-498.
34. Kaldor, J., Day, N., Clarke, E., van Leeuwen, F., Henry-Amar, M., Fiorentino, M., Bell, J., Pedersen, D., Band, P., Assouline, D., Koch, M., Choi, W., Prior, P., Blair, V., Langmark, F., Kirn, V., Neal, F., Peters, D., Pfeiffer, R., Karjalainen, S., Cuzick, J., Sutcliffe, S., Somers, R., Pellae-Cosset, B., Pappagallo, G., Fraser, P., Storm, H., and Stovall, M. 1990. Leukemia following Hodgkin's disease. N. Engl. J. Med. 322:7-12.
35. Larson, R. 2000. Myeloid leukemia after cytotoxic therapy and other hematotoxins. J. Toxicol. Environ. Health A 61:381-386.
36. Larson, R. A., LeBeau, M. M., Vardiman, J. W., and Rowley, J. D. 1996. Myeloid leukemia after hematotoxins. Environ. Health Perspect. 104(suppl. 6):1303-1307.
37. Leone, G., Mele, L., Pulsoni, A., Equitani, F., and Pagano, L. 1999. The incidence of secondary leukemias. Haematologica 84:937-945.
38. Levine, E. G., and Bloomfield, C. D. 1992. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sem. Oncol. 19:47-84.
39. Lin, H., and Teitell, M. 2005. Second malignancy after treatment of pediatric Hodgkin Disease. J. Pediatr. Hematol. Oncol. 27:28-36.
40. Loning, L., Zimmermann, M., Reiter, A., Kaatsch, P., Henze, G., Riehm, H., and Schrappe, M. 2000. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in children: Significantly lower risk without cranial radiotherapy. Blood 95:2770-2775.
41. Makri, A., Goveia, M., Balbus, J., and Parkin, R. 2004. Children's susceptibility to chemicals: A review by developmental stage. J. Toxicol. Environ. Health B 7:417-435.
42. Mantel, N. 1966. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:163-170.
43. Marsoni, S., Ungerleider, R., Hurson, S., Simon, R., and Hammershaimb, L. 1985. Tolerance to anti-neoplastic agents in children and adults. Cancer Treatment Rep. 69:1263-1269.
44. Mauch, P., Kalish, L., Marcus, K., Coleman, N., Krill, E., and Tarbell, N. 1996. Second malignancies after treatment for laparotomy stages IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625-3632.
45. Meadows, A., Baum, E., Fossati-Bellani, F., Green, D., Jenkin, R., Sallan, S., Strong, L., and Voute, P. 1985. Second malignant neoplasms in children: An update from the Late Effects Study Group. J. Clin. Oncol. 3:532-538.
46. Meadows, A., Obringer, A. M. O., Baum, E., and Ruymann, F. 1989. Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med. Pediatr. Oncol. 17:477-484.
47. Metayer, C., Lynch, C., Clarke, A., Glimelius, B., Storm, H., Pukkala, E., Joensuu, T., van Leeuwen, F., van't Veer, M., Curtis, R., Holowaty, E., Andersson, M., Wiklund, T., Gospodarowicz, M., and Travis, L. 2000. Second cancers among long-term survivors of Hodgkin's disease in childhood and adolescence. J. Clin. Oncol. 18:2435-2443.
48. Moloney, W. C. 1987. Radiogenic leukemia revisited. Blood 70:905.
49. Neglia, J., Friedman, D., Yasui, Y., Mertens, A., Hammond, S., Stovall, M., Donaldson, S., Meadows, A., and Robinson, L. 2001. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 93:618-629.
50. Ng, A., Bernado, P., Weller, E., and Mauch, P. 2002. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996.
51. Olsen, J., Garwicz, S., Hertz, H., Jonmundsson, G., Langmark, F., Lannning, M., and Tulinius, H. 1993. Second malignant neoplasms after cancer in childhood or adolescence. Br. Med. J. 307:1030-1036.
52. Park, D. J., and Koeffler, H. P. 1996. Therapy-related myelodysplastic syndromes. Sem. Hematol. 33:256-273.
53. Paxton, M. B., Chinchilli, V. M., Brett, S. M., and Rodricks, J. V. 1994. Leukemia risk associated with benzene exposure in the Pliofilm cohort: I. Mortality update and exposure distribution. Risk Anal. 14:147-154.
54. Pedersen-Bjergaard, J. 1995. Therapy-related myelodysplasia and acute leukemia. Leukocyte Lymphoma 15(suppl. 1):11-12.
55. Pedersen-Bjergaard, J., Larsen, S., Struck, J., Hansen, H., Specht, L., Ersboll, J., Hansen, M., and Nissen, N. 1987. Risk of therapy related leukemia and pre-leukemia after Hodgkin's disease: Relation to age, cumulative dose of alkylating agents and time from chemotherapy. Lancet 11:83-89.
56. Pedersen-Bjergaard, J., Philip, P., Larsen, S.O., Andersson, M., Daugaard, G., Ersboll, J., Hansen, S.W., Hou-Jensen, K., Nielsen, D., Sigsgaard, T.C., Specht, L., and Osterlind, K. 1993. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7:1975-1986.
57. Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H., and Nerlov, C. 2002. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99:1909-1912.
58. Preston, D.L., Kusumi, S., Tomonaga, M., Izumi, S., Ron, E., Kuramoto, A., Kamada, N., Dohy, H., Matsui, T., Nonaka, H., Thompson, D.E., Soda, M., and Mabuchi, K. 1994. Cancer incidence in atomic bomb survivors. Part III: Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat. Res. 137:S68-S97.
59. Pui, C.-H., Behm, F. G., Raimondi, S. C., Dodge, R. K., George, S. L., Rivera, G. K., Mirro, J., Jr., Kalwinsky, D. K., Dahl, G. V., Murphy, S. B., Crist, W. M., and Williams, D. L. 1989. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N. Engl. J. Med. 321:136-142.
60. Pui, C., Hancock, M., Raimondi, S., Head, D., Thompson, E., Wilimas, J., Kun, L., Bowman, L., Christ, W., and Pratt, C. 1990. Myeloid neoplasia in children treated for solid tumours . Lancet. 336:417-421.
61. Pui, C., Ribeiro, R., Hancock, M., Rivera, G., and Evans, W. 1991. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med. 235:1682-1687.
62. Pui, C., Schrappe, M., Ribeiro, R., and Neimeyer, C. 2004. Childhood and adolescent lymphoid and myeloid leukemia. Hematology (American Society of Hematology Educational Program Book), 118-145.
63. Ries, L. A. G., Eisner, M. P., Kosary, C. L., Hankey, B. F., Miller, B. A., Clegg, L., Mariotto, A., Feuer, E. J., and Edwards, B. K., eds. 2005. SEER cancer statistics review, 1975-2002. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005.
64. Rinsky, R. A., Young, R. J., and Smith, A. B. 1981. Leukemia in benzene workers. Am. J. Ind. Med.2:217-245.
65. Rinsky, R. A., Smith, A. B., Hornung, R. W., Filloon, T. G., Young, R. J., Okun, A. H., and Landrigan, P. J. 1987. Benzene and leukemia: An epidemiologic risk assessment. N. Engl. J. Med. 316:1044-1050.
66. Rossi, D., Bryder, D., Zahn, J., Ahlenius, H., Sonu, R., Wagers, A., and Weissman, I. 2005. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc. Natl. Acad. Sci. USA 102:9194-9199.
67. Rowley, J. D., and Le Beau, M. M. 1989. Cytogenetic and molecular analysis of therapy-related leukemia. Ann. NY Acad. Sci. 567:130-140.
68. Rowley, J. D., Golomb, H. M., and Vardiman, J. W. 1981. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 58:759-767.
69. Rushton, L., and Romaniuk, H. 1997. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom. Occup. Environ. Med. 54:152-166.
70. Ryan, D. H., Nuccie, B. L., Ritterman, I., Liesveld, J. L., Abboud, C. N., and Insel, R. A. 1997. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood 89:929-940.
71. Sankila, R., Garwicz, S., Olsen, J., Dollner, H., Hertz, A., Moller, T., and Tulinus, H. 1996. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study on the 5 Nordic countries. J. Clin. Oncol. 14:1442-1446.
72. Schnatter, R. 2000. Petroleum worker studies and benzene risk assessment. J. Toxicol. Environ. Health A 61:433-437.
73. Schwartz, C. 2005. Special issues in pediatric Hodgkin's disease. Eur. J. Haematol.. Suppl. July:55-62.
74. Shulman, L. 1993. The biology of alkylating-agent cellular injury. Hematol./Oncol. Clin. North Am. 7:325-335.
75. Snyder, R. 2000. Overview of the toxicology of benzene. J. Toxicol. Environ. Health A 61:339-346.
76. Swerdlow, A., Douglas, A., Hudson, V., Hudson, B., and MacLennan, K. 1993. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: Relationship to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br. J. Cancer 68:1006-1011.
77. Tester, W., Kinsella, T., Waller, B., Makuch, R., Kelley, P., Glatstein, E., and DeVita, V. 1984. Second malignant neoplasms complicating Hodgkin's disease: The National Cancer Institute experience. J. Clin. Oncol. 2:762-769.
78. Thomson, A., and Wallace, W. 2002. Treatment of paediatric Hodgkin's disease: A balance of risks. Eur. J. Cancer 38:468-477.
79. Tucker, M., Meadows, A., Boice, J., Stovall, M., Oberlin, O., Stone, B., Birch, J., Voute, P., Hoover, R., and Fraumeni, J. 1987. Leukemia after therapy with alkylating agents for childhood cancer. J. Natl. Cancer Inst. 78:459-464.
80. U.S. Environmental Protection Agency, Risk Assessment Forum. 2005. Supplemental guidance for assessing susceptibility from early-life exposures to carcinogens. EPA/630/R-03/003F. Federal Register.
81. Valagussa, P., Santoro, A., Fossati-Bellani, F., Banfi, A., and Bonadonna, G. 1986. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J. Clin. Oncol. 4: 830-837.
82. van der Velden, J., Putten, W., Guinee, V., Pfeiffer, G., van Leeuwen, F., van der Linden, E., Vardomskaya, I., and Eghbali, H. 1988. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int. J. Cancer 42:252-255.
83. van Leeuwen, F., Klokman, W., van't Veer, M., and Aleman, B. 2000. Long-term risk of second malignancies in survivors of Hodgkin's disease treated during adolescence or young adulthood. J. Clin. Oncol. 18:487-497.
84. Wegelius, R. 1992. Bone marrow dysfunctions preceding acute leukemia in children: A clinical study. Leukocyte Res.16:71-76.
85. White, M. C., Infante, P. F., and Chu, K. C. 1982. A quantitative estimate of leukemia mortality associated with occupational exposure to benzene. Risk Anal. 2:195-204.
86. Winick, N. J., McKenna, R. W., Shuster, J. J., Schneider, N. R., Borowitz, M. J., Bowman, W. P., Jacaruso, D., Kamen, B. A., and Buchanan, G. R. 1993. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J. Clin. Oncol. 11:209-217.
87. Wolden, S., Lamborn, K., Cleary, S., Tate, D., and Donaldson, S. 1998. Second cancers following pediatric Hodgkin's disease. J. Clin. Oncol. 16:536-544.
88. Wong, O. 1995. Risk of acute myeloid leukemia and multiple myeloma in workers exposed to benzene. Occup. Environ. Med. 52; 380-384.
89. Wong, O. 2000. Recent findings and new initiatives for epidemiologic research on benzene. J. Toxicol. Environ. Health A 61:457-466.
90. Yin, S.-N., Li, G.-L., Tain, F.-D., Fu, Z.-I., Jin, C., Chen, Y.-J., Luo, S.-J., Ye, P.-Z., Zhang, J.-Z., Wang, G.-C., Zhang, X.-C., Wu, H.-N., and Zhong, Q.-C. 1987. Leukemia in benzene workers: A retrospective cohort study. Br. J. Ind. Med. 44:124-128.